Cyberonics, Inc. Reports Third Quarter Results Conference Call Replay Information

Apr 26, 2001, 01:00 ET from Cyberonics, Inc.

    HOUSTON, April 26 /PRNewswire/ -- Cyberonics, Inc. (Nasdaq: CYBX)
 yesterday held a conference call and internet slide presentation to discuss
 its third quarter results.
     A replay of this conference call will be available beginning today,
 Thursday, April 26, 2001, until Wednesday, May 2, 2001 at 5:00 p.m. EDT by
 dialing 800-642-1687 (if dialing from within the U.S.) and 706-645-9291 (if
 dialing from outside the U.S.).  The conference ID is 792498.  The slide
 presentation will be posted on the Company website, www.cyberonics.com.
     Cyberonics, Inc. (www.cyberonics.com) was founded in 1987 to design,
 develop and market medical devices for the treatment of epilepsy and other
 debilitating disorders using a unique therapy, vagus nerve stimulation.  The
 Company's initial target market is epilepsy, the world's second most prevalent
 neurological disorder, which is characterized by recurrent seizures.  Vagus
 Nerve Stimulation (VNS(TM)) with the Cyberonics NeuroCybernetic Prosthesis
 (NCP(R)) System was approved by the FDA on July 16, 1997 for use as an
 adjunctive therapy in reducing the frequency of seizures in adults and
 adolescents over 12 years of age with medically refractory partial onset
 seizures.  In addition to the U.S., the NCP System is currently approved for
 sale as a treatment for epilepsy in all the member countries of the European
 Union, Canada, Australia and other markets.  VNS delivered by the NCP System
 is at various levels of investigational clinical study as a potential
 treatment for depression, obesity and Alzheimer's disease.  Earlier this year,
 Cyberonics received CE Mark Approval to sell VNS in the member countries of
 the European Union and Canada as a treatment for patients with treatment
 resistant or recurrent depression.
     NCP is a registered trademark of Cyberonics, Inc.  VNS is a trademark of
 Cyberonics, Inc.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X61225634
 
 

SOURCE Cyberonics, Inc.
    HOUSTON, April 26 /PRNewswire/ -- Cyberonics, Inc. (Nasdaq: CYBX)
 yesterday held a conference call and internet slide presentation to discuss
 its third quarter results.
     A replay of this conference call will be available beginning today,
 Thursday, April 26, 2001, until Wednesday, May 2, 2001 at 5:00 p.m. EDT by
 dialing 800-642-1687 (if dialing from within the U.S.) and 706-645-9291 (if
 dialing from outside the U.S.).  The conference ID is 792498.  The slide
 presentation will be posted on the Company website, www.cyberonics.com.
     Cyberonics, Inc. (www.cyberonics.com) was founded in 1987 to design,
 develop and market medical devices for the treatment of epilepsy and other
 debilitating disorders using a unique therapy, vagus nerve stimulation.  The
 Company's initial target market is epilepsy, the world's second most prevalent
 neurological disorder, which is characterized by recurrent seizures.  Vagus
 Nerve Stimulation (VNS(TM)) with the Cyberonics NeuroCybernetic Prosthesis
 (NCP(R)) System was approved by the FDA on July 16, 1997 for use as an
 adjunctive therapy in reducing the frequency of seizures in adults and
 adolescents over 12 years of age with medically refractory partial onset
 seizures.  In addition to the U.S., the NCP System is currently approved for
 sale as a treatment for epilepsy in all the member countries of the European
 Union, Canada, Australia and other markets.  VNS delivered by the NCP System
 is at various levels of investigational clinical study as a potential
 treatment for depression, obesity and Alzheimer's disease.  Earlier this year,
 Cyberonics received CE Mark Approval to sell VNS in the member countries of
 the European Union and Canada as a treatment for patients with treatment
 resistant or recurrent depression.
     NCP is a registered trademark of Cyberonics, Inc.  VNS is a trademark of
 Cyberonics, Inc.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X61225634
 
 SOURCE  Cyberonics, Inc.